Stocks
Cytokinetics, IncorporatedCYTK
NASDAQHealthcareBiotechnology$60.06+0.10%
Price as of · delayed, not real-time
Focused on developing novel muscle-targeted therapies for diseases with significant unmet medical needs, this biopharmaceutical firm is known for its late-stage cardiac muscle activators. Investors monitor Cytokinetics for its potential in treating heart failure and neuromuscular disorders, with key pipeline candidates like aficamten drawing attention.
Market Cap: $7.4B52W Range: $29.31 – $70.98
Congressional Interest in Cytokinetics, Incorporated (CYTK)
2 members of Congress have disclosed 3 trades in Cytokinetics, Incorporated (CYTK), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
2
Sells
1
Who in Congress Is Trading CYTK?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-10-09 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-06-17 | Lisa McClain | sell | $1K – $15K |
| 2025-06-11 | Lisa McClain | buy | $1K – $15K |